Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography

Xiawei Li,a,b,c,* Yidong Wan,d,* Jianyao Lou,a,b,c Lei Xu,d Aiguang Shi,a,b,c Litao Yang,e Yiqun Fan,f Jing Yang,d Junjie Huang,g Yulian Wu,a,b,c,** and Tianye Niu,d,h,***

aDepartment of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
bKey Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Cancer Institute, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
cCancer Center, Zhejiang University, Hangzhou, Zhejiang, China
dInstitute of Translational Medicine, Zhejiang University, Hangzhou, Zhejiang, China
eDepartment of Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
fDepartment of Surgery, Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China
gDepartment of Surgery, Changxing People’s Hospital, Huzhou, Zhejiang, China
hDepartment of Radiation Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Summary

Background The high recurrence rate after radical resection of pancreatic ductal adenocarcinoma (PDAC) leads to its poor prognosis. We aimed to develop a model to preoperatively predict the risk of recurrence based on computed tomography (CT) radiomics and multiple clinical parameters.

Methods Datasets were retrospectively collected and analysed of 220 PDAC patients who underwent contrast-enhanced computed tomography (CE-CT) and received radical resection at 3 institutions in China between 2013 and 2017, with 153 from one institution as a training set, the remaining 67 as a validation set. For each patient, CT radiomics features were extracted from intratumoral and peritumoral regions to establish intratumoral, peritumoral and combined radiomics models using artificial neural network (ANN) algorithm. By incorporating clinical factors, radiomics-clinical nomograms were finally built by multivariable logistic regression analysis to predict 1- and 2-year recurrence risk.

Findings The developed radiomics model integrating intratumoral and peritumoral radiomics features was superior to the conventionally constructed model merely using intratumoral radiomics features. Further, radiomics-clinical nomograms outperformed other models in predicting 1-year recurrence with an area under the receiver operating characteristic curve (AUROC) of 0.916 (95%CI, 0.860-0.955) in the training set and 0.764 (95%CI, 0.644-0.859) in the validation set, and 2-year recurrence with an AUROC of 0.872 (95%CI: 0.809-0.921) in the training set and 0.773 (95%CI, 0.654-0.866) in the validation set.

Interpretation This study has developed and externally validated a radiomics-clinical nomogram integrating intratumoral and peritumoral CT radiomics signature as well as clinical factors to predict the recurrence risk of PDAC after radical resection, which will facilitate optimized and individualized treatment strategies.

Funding This work was supported by the National Key R&D Program of China [grant number: 2018YFE0114800], the General Program of National Natural Science Foundation of China [grant number: 81772362, 2017; 81871351, 2018], the Fundamental Research Funds for the Central Universities [grant number: 2021FZZX005-08], and Zhejiang Provincial Key Projects of Technology Research [grant number: WKJ-ZJ-2033].

**Corresponding author: Yulian Wu, M.D., Ph.D., Department of surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310000, Tel: +86-571-87784604; Fax: +86-571-87784604
***Corresponding author: Tianye Niu, Ph.D., Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
E-mail addresses: yulianwu@zju.edu.cn (Y. Wu), tyniu@zju.edu.cn (T. Niu).
* Xiawei Li and Yidong Wan contributed equally to this article.

www.thelancet.com Vol 43 Month January, 2022
Key words: PDAC; Recurrence; Radical surgery; Radiomics; PTV; ITV; Nomogram

Research in context

Evidence before this study
So far, due to lack of effective preoperative assessment, the proneness for early recurrence after radical resection still remains one of the major barriers to curing patients with PDAC. Prior studies involving pancreatic CT radiomics mainly focused on the features from intratumoral area to predict survival and treatment response with only poor to moderate performance.

Added value of this study
This is the first study to build and validate clinical-radiomics models that preoperatively predict recurrence risk of PDAC using not only intratumoral, but also peritumoral CT radiomics features together with clinical factors in patients eligible for radical resection from multi-institutional datasets.

Implications of all the available evidence
PDAC is distinct from other solid tumors due to its dense stroma. CT radiomics features from peritumoral volume could add additional value to predict its tumor behaviour.

Introduction
With the lowest 5-year survival rate of any epithelial carcinoma at approximately 8%, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide and expected to be the second leading cause of cancer-related mortality.1,2 Only 10-20% of patients were identified at an early stage and able to potentially get cured through radical surgery, due to lack of early clinical symptoms and effective screening approaches.3 However, up to 80% of them will experience recurrence of the disease after curative resection, resulting in a 5-year survival of less than 20%.4,9 Therefore, there is an urgent need to construct efficient predictive models to stratify patients preoperatively and further optimize individualized treatment decision-making.

Currently, development of non-invasive approaches to accurately predict treatment outcomes and prognosis is imperative to improving personalized medicine.10 Several studies have achieved comparable performance in predicting the recurrence of resectable PDAC by building conventional regression-based models merely based on multiple clinicopathological factors.11-13 In recent years, radiomics, as an emerging radiology analogue of “genomics” and “proteomics”, has attracted extensive interest in developing clinical predictive tools for diagnosis, prognosis and therapeutic response of various malignancies.14-17 By using high-throughput mining of intratumoral medical imaging data to extract hidden information, it has also been applied for predicting tumor behavior of PDAC.18-23 While most studies mainly focused on the primary tumor, previous reports have illustrated the unique value of peritumoral region for clinical assessment of carcinous heterogeneity.24-26 So far, it remains unclear whether CT radiomics features from intra- and peritumoral volume could add additional predictive value to traditional clinical models for recurrence risk assessment of PDAC after radical surgery.

Hence, this study intended to develop and validate clinical-radiomics models that preoperatively predict 1- and 2-year recurrence of PDAC using intratumoral/peritumoral CT radiomics features and clinical factors in patients eligible for radical resection. Predicting the risk of recurrence before surgery could help distinguish high-risk patients and select optimal surgical candidates for surgeons, which will further facilitate individualized treatment strategies.27

Materials and Methods

Study design
This study was conducted through four parts as shown in Figure 1. Firstly, we preprocessed CE-CT and extracted radiomics features from intratumoral volume (ITV) and peritumoral volume (PTV). Secondly, we used feature selection method to obtain the optimal features. Then, these selected radiomics features were employed to develop ITV model, PTV model, combined model, clinical model and radiomics-clinical model. Finally, we made a comparison among all models.

Study Population
Data of PDAC patients who underwent radical resection at 3 institutions between January 2013 and December 2017 were obtained. This retrospective analysis was approved by the institutional ethical review boards of three centers including the Second Affiliated Hospital (Institution I), the Forth Affiliated Hospital (Institution II), Zhejiang University school of Medicine and the Zhejiang Cancer Hospital.
The signed informed consent forms were waived. This study was conducted according to the Declaration of Helsinki. The inclusion and exclusion details of patients were as follows: Inclusion criteria: PDAC patients who preoperatively underwent CE-CT and received radical resection at 3 institutions. Exclusion criteria: 1. Patients who had initially borderline resectable/unresectable cancers according to the NCCN guideline; 2. Patients who received neoadjuvant therapy; 3. Patients who did not receive a contrast-enhanced CT scan within two weeks before surgery; 4. Patients lacking complete clinical data or follow-up data; 5. Patients who died from surgical complications within 30 days after surgery; 6. Patients who received consecutive surgical operations.

The final study population consisted of 220 patients (173 patients from the Second Affiliated Hospital, Zhejiang University school of Medicine, 40 patients from the Zhejiang Cancer Hospital, 7 patients from the Forth Affiliated Hospital, Zhejiang University school of Medicine). The training set included the first 153 patients since January 2013 from the first institution and the independent validation set included the last 20 patients from the first institution, 7 patients from the second institution and 40 patients from the third institution (training: validation=7:3). The details of profile and information of patients were presented in Table 1.

Data Collection
Preoperative blood biomarkers including carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, CA125, white blood cell (WBC) count, platelet count, neutrophil count, lymphocyte count, monocyte count, albumin, globulin, aspartate transaminase (AST),
Table 1: Characteristics of patients in the training and validation sets

| Characteristic | Training set (n=153) | Validation set (n=67) | p-value |
|---------------|----------------------|----------------------|---------|
| Age (years)   | 64 (35-90)           | 63 (45-83)           | 0.6461  |
| Sex (Male/Female) | 94/59               | 62/25                | 0.1635  |
| BMI (kg/m²)   | 22.1 (10.52-34.6)    | 22.35 (17.07-27.99)  | 0.9410  |
| CEA (ng/mL)   | 3.1 (0.7-258.5)      | 3.8 (1.01-45.83)     | 0.5705  |
| CA19-9 (U/mL) | 240.4 (2-12000)      | 253.5 (2.2-12000)    | 0.2648  |
| CA125 (U/mL) | 15.2 (2.1-145.6)     | 19.2 (5.5-656.2)     | 0.1476  |
| WBC (10⁹/µL)  | 5.8 (2.3-14.5)       | 5.8 (1.8-13.2)       | 0.5025  |
| Platelet (10⁹/µL) | 185 (67-401)        | 201 (61-335)         | 0.2750  |
| Neutrophil (10⁹/µL) | 3.7 (1-11.68)       | 3.6 (0.9-10.8)       | 0.3332  |
| Lymphocyte (10⁹/µL) | 1.37 (0.44-19.1)    | 1.48 (0.5-3.7)       | 0.7810  |
| Monocyte (10⁹/µL) | 0.46 (0.07-1.32)    | 0.4 (0.1-1.26)       | 0.2245  |
| Albumin (g/L) | 39.6 (23.9-65.4)     | 40.4 (27.7-47.3)     | 0.7273  |
| Globulin (g/L) | 26.5 (14.9-42.4)     | 28.1 (18.4-41.4)     | 0.0565  |
| AST (U/L)     | 42 (9-524)           | 44 (1.6-596)         | 0.9382  |
| ALT (U/L)     | 47 (7-743)           | 51 (8-910)           | 0.6633  |
| ALP (U/L)     | 147 (6-1197)         | 168 (16-1178)        | 0.9587  |
| GGT (U/L)     | 159 (9-2839)         | 201 (10-2298)        | 0.4435  |
| TB (U/L)      | 23 (4.4-358.3)       | 21.3 (4-408.3)       | 0.5572  |
| DB (U/L)      | 6.8 (1-260.2)        | 7.8 (1-263.6)        | 0.8784  |
| AGR           | 1.49 (0.83-2.61)     | 1.41 (0.74-2.18)     | 0.1757  |
| NLR           | 2.72 (0.13-11.90)    | 2.5 (0.67-15.43)     | 0.7617  |
| LMR           | 2.92 (0.63-44.42)    | 3.20 (0.06-17)       | 0.6848  |
| PLR           | 134.92 (10.10-616.92) | 141.54 (60-343.33)  | 0.6960  |

Note: CEA: carcinoembryonic antigen; CA19-9: serum carbohydrate antigen 19-9; WBC: white blood cell; AST: aspartate transaminase; ALT: alanine transaminase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; TB: total bilirubin; DB: direct bilirubin; AGR: albumin-globulin ratio; NLR: neutrophil-lymphocyte ratio; LMR: lymphocyte-monocyte ratio; PLR: platelet-lymphocyte ratio.

Image acquisition and volume of interest (VOI) delineation

The patients in our study underwent an abdominal CE-CT preoperatively. CE-CT scan in Institution I was performed on five CT scanners including a 16-slice CT (Sensation 16, Siemens), a 16-slice CT (BrightSpeed, GE MEDICAL SYSTEMS), a 64-slice CT (SOMATOM Definition AS, GE MEDICAL SYSTEMS), a 320-slice CT (Aquilion ONE, TOSHIBA), an 800-slice CT (SOMATOM Definition Flash, GE MEDICAL SYSTEMS). The CE-CT scan in Institution II was undertaken on two scanners, including a 16-slice CT (BrightSpeed, GE MEDICAL SYSTEMS), a 64-slice CT (SOMATOM Definition AS, GE MEDICAL SYSTEMS). The CE-CT scan in Institution III was undertaken on three scanners, including a 16-slice CT (BrightSpeed, GE MEDICAL SYSTEMS), a 64-slice CT (SOMATOM Definition AS, GE MEDICAL SYSTEMS), a 320-slice CT (Aquilion ONE, TOSHIBA). The scanning voltage of 100 kVp to 120 kVp, tube currents were 240 to 1287 mAs. The slice thickness ranged from 3 to 7.5 mm.

The follow-up of patients after surgery was initially conducted every 3 months in the first two years, every 6 months during years 3 and 4, and then annually. The surveillance protocol included physical examination, serum cancer antigens and abdominoperineal CE-CT. Magnetic resonance imaging (MRI) scan and/or fluorodeoxyglucose positron emission tomography (PET) would be implemented to further clarify ambiguous CT findings every time imaging features were consistent with a potential cancer recurrence.

Feature extraction

To reduce the variation in different scanners, a two-step method of the image preprocessing was conducted before radiomics features extraction. Firstly, to...
different pixel sizes and slice thicknesses of various CE-CT scanners, all the CT slices were resampled to $1 \times 1 \times 1 \mathrm{~mm}^3$ using the bicubic interpolation. Secondly, the images were normalized to 64 grey levels to compensate for the variation of CE-CT scanners. For each ITV and PTV area, 547 radiomics features were extracted covering 7 shape features, 7 histogram features, 22 gray-level co-occurrence matrix (GLCM) features, 13 gray-level run-length matrix (GLRLM) features, 13 gray-level size zone matrix (GLSZM) features, 5 neighborhood gray-tone difference matrix features, and 480 wavelet-based features. Therefore, we could obtain 1094 radiomics features for each patient. Radiomics features extraction process was conducted using the radiomics tools available in MATLAB. More details about the feature extraction methods could be found in the study by Vallières et al. 

Feature selection and model construction
Before the process of feature selection, the extracted features were normalized using the Z-score, with the mean and standard deviation of the features in the training set utilized to normalize the corresponding features in the validation set. To reduce the dimension of radiomics features, we conducted a two-step feature selection approach in the training set. Initially, each significant feature calculated by the Wilcoxon test ($p$-value < 0.05) was maintained. Afterwards, the minimum redundancy maximum relevancy (mRMR) feature selection algorithm was used to select the features most relevant to the status of 1-year recurrence and 2-year recurrence, and the selected features had minimal redundancy among each other. In this study, the artificial neural network (ANN) algorithm (parameter: hidden layer = 3, initial random weight = 0.01, weight decay = 5e-3, maximum number of iterations = 100) was used to construct the prediction model. The area under the receiver operating characteristic (ROC) curve (AUC) value was the scoring criterion to obtain the optimal tumor radiomics features. The ITV model, PTV model and combined model were developed, respectively. A radiomics score was calculated to reflect the risk of tumor recurrence for each patient using the proposed radiomics model. To evaluate the capability of predicting the status of recurrence, the constructed model from the training set was verified in the independent validation set. To obtain the best prediction performance of PTV classifier, we also explored the capability of different PTV models, with the length of edge ranged from 3mm to 7mm.

Clinical-based model and combined radiomics-clinical model construction and evaluation
In addition to the radiomics model, we also constructed clinical model and radiomics-clinical model. The clinical model and radiomics-clinical model were developed by multivariate logistic regression method. The backward step-wise search method with lowest Akaike Information Criterion (AIC) score was used to selected the optimal clinical factors. Then, we used the univariate analysis to select the clinical factors to combine with radiomics score to establish the radiomics-clinical model. The performances of all models were reported using the AUC in the training set and validation set. A Hosmer-Lemeshow (H-L) test was used to evaluate the goodness-of-fit of the radiomics-clinical model. The clinical utility of the models was evaluated with a decision curve analysis (DCA) in two sets. DeLong test was used to measure the differences in ROC curves among all models. The comparison of all the models were carried out in the validation cohorts.
Articles

Statistical Analysis
Statistical analysis was conducted in R v3.4.1 (www.Rproject.org) and MedCalc v15.2.2 (www.medcalc.org). mRMR analysis, plotting of nomograms and calibration curves, H-L test, ROC and AUC, and DCA were performed on the packages “mRMR”, “rms”, “generalhoslem”, “pROC”, and “dca.R”, respectively. The reported significance levels were two-sided and set at 0.05.

This manuscript is compliant with STrengthening the Reporting of OBservational studies in Epidemiology (STROBE). A checklist is provided as an online supplement.

Role of Funding Source
All funding sources played no role in the design of the study; collection, analysis and interpretation of data; in writing the manuscript, and in the decision to submit the paper for publication.

Results

Baseline Characteristics
Baseline clinical characteristics in the training and validation sets were summarized in the Table 1. The median follow-up of the entire population was 18.0 months (95% CI 16.0-20.5). The 1-year recurrence rate was 58.17% and 59.70% for the training set and validation set, respectively. The 2-year recurrence rate was 73.20% and 71.64% for the training set and validation set, respectively. No significant difference was observed in the baseline patient characteristics between the groups, indicating a good consistency of the two datasets. Univariate analysis for the 1-year and 2-year recurrence was performed and only CA19-9 showed statistical significance between recurrence group and non-recurrence group in training and validation sets. Therefore, CA19-9 factor was identified as an independent predictive factor in predicting the risk of recurrence of PDAC after radical resection.

Feature selection and model construction for 1-year recurrence
In this study, three types of prediction models were developed and compared including radiomics model, clinical model and clinical-radiomics model. For the radiomics one, we constructed three sub-models including ITV model, PTV model and the combined model. By univariate analysis, 295 intratumoral radiomics features were found to be significant different between patients with 1-year recurrence and non-recurrence in the training set, 9 of which were finally selected by the mRMR algorithm to build the ITV model with an AUC of 0.851 (95%CI, 0.784-0.903) in the training set and 0.713 (95%CI, 0.589-0.817) in the validation set. In order to construct a PTV model with the best predictive performance, different regions of peritumoral parenchyma ranging from 3mm to 7mm were explored. A total of 270, 230, 229, 214, 209 radiomics features of five separate PTV models (3mm, 4mm, 5mm, 6mm and 7mm), respectively, were selected using univariate analysis. Then, 8, 10, 10, 6, 6 optimal features were accordingly picked up by mRMR method to develop the models using the ANN algorithm. Among them, the PTV7mm presented the best performance in predicting the different status of 1-year recurrence with an AUC of 0.786 (95%CI, 0.713-0.848) for the training set and 0.764 (95%CI, 0.528-0.766) for the validation set. To further improve the prediction capability, the intratumoral and peritumoral features were combined to yield higher AUCs in both training (AUC = 0.901 (95%CI, 0.842-0.943)) and validation set (AUC = 0.732 (95%CI, 0.610-0.833)). The rank of mRMR score and univariate analysis for the selected top 15 radiomics features were shown in Figure S1.

Similarly, considering the potential effectiveness of clinical factors, we also constructed the clinical model and radiomics-clinical model. The performance of the clinical factors-based model was inferior to the radiomics models in both two datasets (training set: 0.630 (95%CI, 0.648-0.707); validation set: 0.644 (95%CI, 0.517-0.775)). However, the radiomics-clinical model combined ITV, PTV7mm and CA19-9 levels presented the optimal performance in predicting the 1-year recurrence with an AUC of 0.916 (95%CI, 0.860-0.959) in the training set and an AUC of 0.764 (95%CI, 0.644-0.859) in the validation set. The ROC curves for each model were pictured in the Figure 3A and 3B. The H-L test showed a satisfying accuracy of the nomogram for predicting the status of 1-year recurrence both in the training set (p-value=0.7194) and validation set (p-value=0.5929).

By the Delong test, although the radiomics-clinical model was preferred, there was no significant difference in the predictive performance compared with other predictive models in the validation set. The detailed value of p-values among all models were listed in Table S1. Furthermore, the nomogram was visualized in Figure 3E. The DCA showed that the nomogram model (black) presented more area than the model merely developed by clinical factors in two sets which demonstrated the promising clinical decision utility of nomogram. The DCA curves for the two datasets were separately shown in Figure 3C and 3D.

Feature selection and model construction for 2-year recurrence
To further explore the generalization of radiomics model in predicting the recurrence status of pancreatic cancer after radical resection. We employed the similar...
method to construct radiomics model, clinical model and radiomics-clinical model to evaluate the prediction performance for 2-year recurrence. Compared with the other two radiomics models, the combined model also showed the best prediction capability in the validation set (combined model, AUC=0.709 (95%CI, 0.585-0.814); ITV model, AUC=0.648 (95%CI, 0.521-0.701); PTV7mm model, AUC=0.658 (95%CI, 0.532-0.769)). In accordance with the study of 1-year recurrence, the clinical model for 2-year recurrence also achieved the worst prediction performance with a poor AUC of 0.723 (95%CI, 0.645-0.793) in the training set and an AUC of 0.541 (95%CI, 0.415-0.663) in the validation set. Finally, we integrated the CA19-9 level and radiomics scores to establish the radiomics-clinical model, which outperformed others in predicting the status of 2-year recurrence (training set: AUC=0.872 (95%CI: 0.809-0.921); validation set: AUC=0.773 (95%CI, 0.654-0.866)). The ROC curves for each model were pictured in the Figure 4A and 4B. The nomogram and DCA curves for 2-year recurrence models could be seen in Figure 4C, 4D and 4E. The H-L test showed that non-significant difference was observed between true calibration curves and ideal curves both in the training set (p-value=0.2543) and validation set (p-value=0.2678).
Discussion

Robust assessment tools with satisfying accuracy for individual risk of recurrence after multimodal therapy would minimize unnecessary treatments and thus serve as a decision aid for clinical decision-making. In this study, we have constructed and validated nomograms integrating CT radiomics features and clinical characteristics to predict the recurrence risk of PDAC after curative surgery. It turned out that the combined clinical-radiological models were superior to conventional clinical factors-based ones in predictive capability. Moreover, incorporating additional features from peritumoral regions into the models could further improve their power.

In this study, to ensure the generalizability of the promoted model, only most commonly measured lab test results in various medical centers including cancer antigens, blood routine and biochemical indicators were used in clinical models. Inflammation-based prognostic scores, including albumin-globulin ratio (AGR), lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were calculated as well but with no statistical significance. Other clinical features like nutritional status could be reflected by patients’ BMI, which also showed no statistical significance between recurrence group and non-recurrence group by univariate analysis. In fact, the study population we focused on in this study...
tended to have similar pre-operative nutritional status and Eastern Cooperative Oncology Group (ECOG) performance as they could withstand radical surgery and subsequent adjuvant therapy. Additionally, in alignment with various studies investigating the predictive early recurrence parameters of PDAC, CA19-9 is independently associated with both 1-year and 2-year recurrence risk. To be clear, histopathologic data was not included in this study for the purpose of guiding preoperative decision-making.

So far, due to the paucity of comprehensive and in-depth preoperative assessment, the proneness for early recurrence after radical resection still remains one of the major barriers to curing patients with PDAC. It has been reported that early recurrence within 12 months occur in 50% to 60% of patients considered eligible for surgical resection, and in this study, the number was 58.17% and 59.70% for the training and validation set, respectively. Timely and accurate prediction of recurrence risk is urgently needed to identify patients at high risk, among whom more detailed examination, the use of neoadjuvant therapy, or even the inclusion of these patients into clinical trials could be considered.

Nowadays, radiomics research in oncology is accelerating rapidly, with potential applications in almost every aspect of cancer management. In patients with pancreatic cancer, preoperative CE-CT is the preferred primary imaging modality for the initial evaluation. As is routinely used for screening, staging and monitoring the progression of PDAC, CT scan is relatively faster and more inexpensive compared to MRI, making it more easily available for use. Previous studies involving CT radiomics mainly focused on the features from intratumoral area to predict survival and treatment response with only poor to moderate performance. However, characterized by its dense desmoplastic stroma composed of stromal cells and extracellular matrix, PDAC is distinct from other solid tumors. Recent radiomics reports have revealed the links between cancer behavior and peritumoral features in various malignant neoplasms including esophageal carcinoma, hepatocellular carcinoma, breast cancer, and lung adenocarcinoma, etc. Imaging characteristics of surrounding areas outside tumor itself were found to be able to reflect the subtle change of surrounding microenvironments and provide complementary information on tumor heterogeneity. To date, similar researches regarding PDAC have rarely been reported.

To the best of our knowledge, this is the first study to build and validate clinical-radiomics nomograms that preoperatively predict recurrence risk of PDAC using not only intratumoral, but also peritumoral CT radiomics features in addition to clinical parameters in patients eligible for radical resection from multi-institutional datasets. Although the concept of “radiomics” has been raised for almost a decade since 2012 by Lambin et al, there has never been an article investigating the relationship between CT features and recurrence risk of PDAC after radical resection. We speculate that the unsatisfying predictive capability of models merely based on intratumoral information might account for this delayed progress. Therefore, the great clinical potential of peritumoral radiomics needs to be further exploited in the future. As for the previously reported models simply based on clinicopathological factors regarding this topic, each of them has their own specific drawbacks with either a poor predictive performance (AUROC=0.655), or a lack of external validation, or a very small sample size of less than 40, respectively.

Several limitations of our work deserve to be acknowledged. First, given the retrospective nature of this study, some selection bias might be introduced, and the findings reported herein need to be confirmed in prospective trials. Second, due to the low incidence of PDAC, the relatively limited sample size included might restrict the statistical power for quantifying interpatient variability effects. Additional studies on large-scale datasets from multiple medical institutions are required to further establish the robustness of the proposed nomogram. Notably, although the sample size might be not large compared with other tumors, it was at least not small considering the strict inclusion criteria and was actually larger than most radiomics studies regarding PDAC. Third, the time-consuming and labor-intensive work of manual contouring of region of interest (ROIs) still poses a major bottleneck for implementing cutting-edge radiomics techniques in clinical practice at present. It is worthy looking forward to some novel automatic volumetric segmentation algorithms in PDAC radiomics analysis to simplify the process in the near future.

To conclude, we have developed and validated a comprehensive radiomics-clinical nomogram integrating intra- and peritumoral radiomics signature as well as clinical characteristics to preoperatively predict the recurrence risk of PDAC after radical resection. Radiomics features extracted from CT scan can provide additional prognostic prediction value for patients before surgery, facilitating the non-invasive burgeon of individualized regimens in early treatment course.

Declaration of Competing Interest
The authors declare no potential conflicts of interest.

Data sharing statement
The datasets generated during and analysed during the current study are available by the corresponding author, upon reasonable request.
Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. *Cancers (Basel)* 2019.

31 He J, Pan H, Liang W, Xiao D, Chen X, Guo M, et al. Prognostic Effect of Albumin-to-Globulin Ratio in Patients with solid tumors: A Systematic Review and Meta-analysis. *Journal of Cancer* 2017;8(19):4002–10.

32 Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. *BMJ Cancer* 2020;8(1):1137.

33 Tong Z, Liu L, Zheng Y, Jiang W, Zhao P, Fang W, et al. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: A nomogram-based study. *World Journal of Surgical Oncology* 2017;15(1):1–9.

34 Wang C, He W, Yuan Y, Zhang Y, Li K, Zou R, et al. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. *Liver Int* 2020.

35 Suzuki S, Shimoda M, Shimazaki J, Maruyama T, Oshiro Y, Nishida K, et al. Predictive Early Recurrence Factors of Preoperative Clinico-physiological Findings in Pancreatic Cancer. *European Surgical research* 2018;50(4):57–60. [et al.]

36 Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. *Pancreatology: official journal of the International Association of Pancreatology (IAP)* 2015;15(1):57–60. [et al.]

37 Sugiu T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. *Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract* 2012;16(3):577–83.

38 Groet VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, Timing, and Predictors of Recurrence Following Pancreactectomy for Pancreatic Ductal Adenocarcinoma. *Annals of Surgery* 2018;267(1):316–25.

39 Shim S, Kim S, Song K, Hwang D, Lee J, Park K, et al. Chronicologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients. *Surgery* 2018;164(3):412–22.

40 Abunahel BM, Pontre B, Kumar H, Petrov MS. Pancreas image mining: a systematic review of radiomics. *Eur Radiol* 2021;31(3):5447–67.

41 Lee JW, LH O, Choi M, Choi JY. Impact of F-18 Fluorodeoxyglucose PET/CT and PET/MRI on Initial Staging and Changes in Management of Pancreatic Ductal Adenocarcinoma: A Systemic Review and Meta-Analysis. *Diagnóstico (Bilbao)* 2020;30(6):932.

42 Tammi EP, Bhosale PR, Lee JH. Pancreatic ductal adenocarcinoma: ultrasound, computed tomography, and magnetic resonance imaging features. *Semin Ultrasound CT MR* 2007;28(1):310–8.

43 Hwang SH, Kim HY, Lee EJ, Hwang HK, Park M-S, Kim M-j, et al. Preoperative Clinical and Computed Tomography (CT)-Based Nomogram to Predict Oncologic Outcomes in Patients with Pancreatic Head Cancer Resected with Curative Intent: A Retrospective Study. *Journal of Clinical Medicine* 2019;8(10):1749.

44 Xie T, Wang X, Li M, Tong T, Yu X, Zhou Z. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. *European Radiology* 2020;30(9):2513–24.

45 Nasief H, Zheng C, Schott D, Hall W, Tsai S, Erickson B, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. *npj Precision Oncology* 2019;3(1):1–10.

46 Han X, Li Y, Xu Y, Zhao X, Zhang Y, Yang X, et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. *Nature communications* 2018;9(1).

47 Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *European Journal of Cancer* 2012;48(4):441–6. (Oxford, England: 1990).

48 Okada T, Lingurarut M, Hori M, Summers R, Tomiyama N, Sato Y. Abdominal multi-organ segmentation from CT images using conditional shape-location and unsupervised intensity priors. *Medical image analysis* 2015;26(1):1–18.

49 Farag A, Lu Le, Roth H, Liu J, Turkbey E, Summers R. A Bottom-Up Approach for Pancreas Segmentation Using Cascaded Superpixels and (Deep) Image Patch Labeling. *IEEE transactions on image processing: a publication of the IEEE Signal Processing Society* 2017;26(1):385–99.